Companies: 48,687 Total Market Cap: 127170013462504.63

Hugel

KOSDAQ-145020
Pharmaceutical Preparations
Rank #4641
Market Cap 2.84 B
Volume 18.48
Price 264.12
Change (%) 1.78%
Country or region South Korea South Korea

Hugel's latest marketcap:

2.84 B

As of May 4, 2025, Hugel's market capitalization has reached $2.84 B. According to our data, Hugel is the 4641th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 2.84 B
Revenue (ttm) 264.86 M
Net Income (ttm) 96.43 M
Shares Out 10.76 M
EPS (ttm) 8.51
Forward PE 26.09
Ex-Dividend Date n/a
Earnings Date May 7, 2025
Market Cap Chart
Data Updated: May 4, 2025

Hugel's yearly market capitalization.

Hugel has seen its market value grow from ₩2,352.30 B to ₩3,874.10 B since 2020, representing a total increase of 64.69% and an annual compound growth rate (CAGR) of 12.25%.
Date Market Cap Change (%)
April 25, 2025 ₩3,874.10 B 25.41%
December 30, 2024 ₩3,089.09 B 84.38%
December 28, 2023 ₩1,675.39 B 4.84%
December 29, 2022 ₩1,597.99 B -14.29%
December 30, 2021 ₩1,864.45 B -20.74%
December 30, 2020 ₩2,352.30 B

Company Profile

About Hugel, Inc.

Hugel, Inc. is a biopharmaceutical company specializing in the development and manufacturing of innovative medical solutions. Headquartered in Chuncheon-si, South Korea, the company operates both domestically and internationally, delivering high-quality products across multiple therapeutic areas.

Key Products

  • Botulinum Toxin: A white injectable dry powder used for:
    • Treatment of essential eyelid convulsion in adults (18+)
    • Improvement of severe lasso wrinkles (ages 18-65)
    • Upper limb stroke treatment
    • Dynamic equinus foot deformity treatment in children with cerebral palsy (2+)
    • Enhancement of external angles related to orbicularis oculi muscle activity (ages 19-65)

    Brands: Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, Botoshot

  • Hyaluronic Acid Filler: Under the Dermalax and The Chaeum brands
  • Cosmetics: Marketed under the Wellage brand
  • Medical Devices: Sold under the BlueRose brand

Company Background

Founded in 2001, Hugel, Inc. has established itself as a leader in biopharmaceutical innovation, serving patients and healthcare professionals worldwide.

Frequently Asked Questions

As of May 4, 2025, Hugel (including the parent company, if applicable) has an estimated market capitalization of $2.84 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Hugel global market capitalization ranking is approximately 4641 as of May 4, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region South Korea
Founded 2001
IPO Date n/a
Employees 594
CEO Ji-hoon Sohn
Sector
Industry Pharmaceutical Preparations
Address 61-20, Sinbuk-ro
Chuncheon-si, 24206
South Korea